Denali Therapeutics (DNLI) Competitors $13.26 +0.10 (+0.76%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$13.43 +0.17 (+1.28%) As of 09/16/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DNLI vs. BEAM, ROIV, RVMD, GRFS, RYTM, LEGN, ABVX, RNA, CYTK, and AXSMShould you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Beam Therapeutics (BEAM), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Denali Therapeutics vs. Its Competitors Beam Therapeutics Roivant Sciences Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Abivax Avidity Biosciences Cytokinetics Axsome Therapeutics Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability. Is DNLI or BEAM more profitable? Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -661.31%. Denali Therapeutics' return on equity of -40.79% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -40.79% -36.39% Beam Therapeutics -661.31%-43.15%-31.06% Does the media prefer DNLI or BEAM? In the previous week, Beam Therapeutics had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for Beam Therapeutics and 7 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.40 beat Beam Therapeutics' score of 0.84 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in DNLI or BEAM? 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend DNLI or BEAM? Denali Therapeutics currently has a consensus price target of $33.50, indicating a potential upside of 152.64%. Beam Therapeutics has a consensus price target of $46.40, indicating a potential upside of 102.53%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Denali Therapeutics is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 3 Strong Buy rating(s) 3.12Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 3 Strong Buy rating(s) 3.08 Which has more risk and volatility, DNLI or BEAM? Denali Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Which has higher earnings and valuation, DNLI or BEAM? Beam Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M5.87-$422.77M-$2.80-4.74Beam Therapeutics$63.52M36.49-$376.74M-$4.50-5.09 SummaryDenali Therapeutics beats Beam Therapeutics on 10 of the 16 factors compared between the two stocks. Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNLI vs. The Competition Export to ExcelMetricDenali TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.92B$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-4.7421.1675.8626.51Price / Sales5.87446.35528.72123.58Price / CashN/A45.4037.1760.46Price / Book1.559.6212.796.29Net Income-$422.77M-$53.28M$3.28B$270.51M7 Day Performance-9.43%1.01%0.81%1.95%1 Month Performance-9.80%4.58%4.60%6.33%1 Year Performance-56.78%8.35%70.39%25.62% Denali Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNLIDenali Therapeutics4.3593 of 5 stars$13.26+0.8%$33.50+152.6%-56.3%$1.92B$330.53M-4.74430Positive NewsBEAMBeam Therapeutics3.0226 of 5 stars$19.94-4.5%$48.45+143.0%-10.6%$2.11B$63.52M0.00510Analyst DowngradeROIVRoivant Sciences2.8008 of 5 stars$12.91-0.1%$16.38+26.8%+17.8%$8.82B$29.05M0.00860RVMDRevolution Medicines4.2693 of 5 stars$41.06+1.4%$72.00+75.4%+0.4%$7.57B$11.58M0.00250Positive NewsInsider TradeAnalyst RevisionGRFSGrifols3.8873 of 5 stars$10.11-0.2%$10.30+1.9%+6.4%$6.96B$7.81B0.0023,822Positive NewsRYTMRhythm Pharmaceuticals3.2982 of 5 stars$99.77-2.3%$101.57+1.8%+92.9%$6.78B$130.13M0.00140Positive NewsLEGNLegend Biotech3.1915 of 5 stars$34.62-4.0%$74.22+114.4%-33.0%$6.66B$627.24M0.002,609Positive NewsABVXAbivax2.7264 of 5 stars$90.00+2.2%$92.33+2.6%+616.7%$6.65BN/A0.0061Short Interest ↑RNAAvidity Biosciences2.0792 of 5 stars$48.05-4.6%$67.00+39.4%-0.7%$6.48B$10.90M0.00190Analyst ForecastCYTKCytokinetics4.3654 of 5 stars$52.09-1.7%$75.38+44.7%-12.3%$6.34B$18.47M-10.21250Positive NewsInsider TradeAXSMAxsome Therapeutics4.908 of 5 stars$129.29+3.3%$177.86+37.6%+23.5%$6.25B$385.69M0.00380Positive NewsInsider Trade Related Companies and Tools Related Companies Beam Therapeutics Competitors Roivant Sciences Competitors Revolution Medicines Competitors Grifols Competitors Rhythm Pharmaceuticals Competitors Legend Biotech Competitors Abivax Competitors Avidity Biosciences Competitors Cytokinetics Competitors Axsome Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNLI) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
